|
Cytos Biotechnology soars on results of asthma-drug study
FierceBiotech After closing out a failed Novartis partnership in January, Cytos Biotechnology has registered some upbeat data from a mid-stage study of its lead drug against allergic asthma. On the news, Zurich-based Cytos' shares jumped 14% as of early this morning … Cytos Rises After Asthma Drug Succeeds in Trial: Zurich Mover The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study … |
View full post on asthma – Google News
